Scientific Name(s): Crocus sativus L. Family: Iridaceae

Common Name(s): Saffron , za'faran


Saffron has widespread traditional uses. It has demonstrated efficacy in mild to moderate depression; however, a limited number of quality clinical trials exist. Potential exists for a role in the treatment of cancer and age-related macular degeneration.


Clinical trials are lacking to guide dosage of saffron. A dosage of 30 mg daily in 2 divided doses has been investigated for the treatment of mild to moderate depression and in premenstrual syndrome. Doses of up to 1.5 g/day of saffron are thought to be safe; toxic effects have been reported at 5 g.


Contraindications have not yet been identified. High doses should be avoided in pregnancy.


Avoid use. Amounts of more than 5 g, which is greater than amounts used in food, have uterine stimulant and abortifacient effects. There is no information regarding use in lactation.


None well documented. Interaction with platelet antiaggregating drugs is theoretically possible. Crocetin binds strongly to serum albumin.

Adverse Reactions

Clinical trials evaluating saffron in depression at dosages of 30 mg daily reported no statistically significant adverse events versus either placebo or comparator drugs. Reported adverse effects include nausea, vomiting, and headache. Death has resulted from the ingestion of doses of more than 10 g. Allergic reactions are uncommon; however, occupational allergy, including rhinoconjunctivitis, bronchial asthma, and cutaneous pruritus, has been reported. Case reports of anaphylaxis exist.


Information is limited.


True saffron is native to Asia Minor (Anatolia) and southern Europe, with the majority of the world production based in Iran. Its blue-violet, lily-shaped flowers contain the orange stigmas (part of the pistil) and red style branches that are collected to produce the saffron spice. The plant is a bulbous perennial and grows 15 to 20 cm in height. Mature stigmas are collected by hand during a short blooming season. Over 200,000 dried stigmas, obtained from about 70,000 flowers, yield 0.5 kg of true saffron. Saffron may cost as much as $30 per ounce in the American market.

True saffron should not be confused with Carthamus tinctorius L. (family Asteraceae), also called American saffron (safflower, Indian safflower), that is produced from the tubular florets and is a lighter red than true saffron. The two are often used for the same purposes, and the less expensive American saffron is sometimes used to adulterate true saffron. 1 , 2 , 3 , 4 , 5


Saffron use has been traced to ancient Egyptian and Roman times when it was first used for medicinal value, and only later becoming valued as a spice and dye. The word saffron is thought to originate from the Arabic za'faran , meaning yellow. Folkloric uses of saffron have included its use as a sedative, expectorant, aphrodisiac, emmenagogue, and diaphoretic. During the 16th through 19th centuries, saffron was used in various opioid preparations, including laudanum and “black-drop” for pain relief.

Saffron has been used for a wide variety of ailments, including cramps, asthma, menstrual disorders, in liver disease, for pain and as an antidepressant and aphrodisiac. In the Indian Ayurvedic health system it is considered an adaptogen. However, the Complete German Commission E Monographs negatively evaluated saffron for use in cramps or asthma. United States patents were issued in the 1970s for the proposed use of crocetin in the treatment of skin papillomas, spinal cord injuries, hypertension, and cerebral edema in cats. Various patents exist for saffron in combination with other agents. 3 , 4 , 6 , 7 , 8


The stigmas of C. sativus contain the primary pigment crocin, as well as anthocyanin, alpha- and beta-carotene, and zeaxanthin pigments, and the vitamins riboflavin and thiamine. 3 , 9 , 10 , 11 The major carotenoid derivatives crocetin, picrocrocin, and safranal are found in saffron. The characteristic taste of the spice is attributed to the glycoside picrocrocin, while safranal is considered to be the main odiferous constituent achieved through hydrolysis of picrocrocin. 3 , 12 , 13

Crocin is a mixture of glycosides: crocetin, a dicarboxylic terpene lipid, and alpha-crocin, a digentiobiose ester of crocetin. Cis- and trans-crocetin dimethyl esters have also been identified. 13 Similar compounds have been isolated from other members of the Iridaceae family. Gardenidin, a compound obtained from gardenias, is identical to crocetin.

The essential oil derived from saffron is a complex mixture of more than 30 components, mainly terpenes and their derivatives. A review of the volatile compounds has been published. 12

Uses and Pharmacology


Saffron appears to be selectively cytotoxic by mechanisms not fully understood, 3 , 14 , 15 , 16 inhibiting proliferation and disease progression while healthy cells remain viable. 3 , 4 , 10 , 17 , 18 , 19 Effects are shown to be concentration- and time-dependent. 3 , 20 The toxicity of cytostatic drugs, such as cisplatin, is reduced with concurrent administration of saffron extracts without affecting the drugs' antitumor activity. 3 , 4 , 21 The lifespan of animals with induced carcinomas was increased with the administration of saffron extracts. 22 , 23 , 24

Reviews of the potential role of saffron extracts in cancer therapy have been published. Although promising, data is limited to in vitro and animal experimentation; clinical trials are lacking. 3 , 4 , 25

Cardiovascular effects

Clinical trials are limited. Epidemiologic evidence suggests that the low incidence of cardiovascular disease in parts of Spain may be related to the liberal, almost daily consumption of saffron. Algae in Japanese diets that also contain crocetin may have a similar protective effect. 26

Studies in animals have shown that aqueous and ethanolic saffron extracts reduce blood pressure in a dose-dependent manner. 3 In a study among healthy volunteers, saffron 400 mg daily for 7 days resulted in decreases in standing systolic, but not diastolic, blood pressure and mean arterial pressure. 27

Rabbits with induced hyperlipidemia showed decreased cholesterol and triglyceride levels and reduced vascular damage when treated with crocetin. Hypoxia at the vascular wall was also reduced. 28 , 29 However, in a study of healthy volunteers, saffron 400 mg daily for 7 days had no effect on the lipid profile. 27

Crocetin produced an 80% increase in the oxygen diffusivity of plasma 29 and binds strongly to serum albumin. 11 , 30 An antioxidant effect was demonstrated in human platelets with the inhibition of lipid peroxidation, 11 , 31 , 32 while improved antioxidant status was shown in patients with coronary artery disease given saffron 50 mg extract twice daily. 3 , 4


A number of well-designed clinical trials have been conducted evaluating the efficacy of saffron 30 mg daily over 6 to 8 weeks in mild to moderate depression. 33 , 34 , 35 , 36 , 37 The studies found saffron to be more effective than placebo and at least equivalent to therapeutic doses of imipramine and fluoxetine using the Hamilton Depression Rating Scale. No significant differences were found in adverse events in any of the studies. However, the studies involved small sample sizes (40 patients) and were conducted by the same group of researchers, within a non–Western population. 38 , 39 The cost of stigma-based saffron capsules is significant, and 2 of the trials evaluated petal-derived saffron with satisfactory results. 33 , 36 The same researchers favorably evaluated saffron for the relief of premenstrual syndrome. 40


In vitro experiments demonstrated a concentration-dependent protective effect of the carotenoid crocin and its analogs on animal retina. 41 , 42 Increased blood flow in the retina and choroid has been demonstrated. 41 As a dietary supplement, saffron extract prevented retinal damage in rats, 43 and it may have a role in the treatment of ischemic retinopathy and age-related macular degeneration. 3

Other uses

Ethanol-impaired memory was improved in mice treated with crocin, but not crocetin, and it may have a direct effect on the hippocampus. 44 Other trials have been conducted in animals to evaluate the effect of saffron on learning behavior, memory, and neuronal cell death. 3

A study in mice concluded that the stigma and petal from saffron demonstrated antinociceptive and anti-inflammatory effects. 45

Saffron tea has been used in the management of psoriasis. 46

Saffron combined with hematoxylin-eosin or hematoxylin-phyloxin is used as a staining method in various procedures (ie, examining giant cell tumors, cell death, and airway smooth muscle orientation). 47 , 48 , 49


Clinical trials are lacking to guide dosages of saffron.

A dosage of 30 mg daily in 2 divided doses has been evaluated for the treatment of mild to moderate depression, and in premenstrual syndrome. 33 , 34 , 35 , 36 , 37

Improved antioxidant status was shown in patients with coronary artery disease given saffron 50 mg extract twice daily in an older trial. 3 , 4

Doses of up to saffron 1.5 g daily are thought to be safe; toxic effects have been reported for 5 g dosages. 4


There is limited evidence to support the emmenagogue or abortifacient effects attributed to saffron. In a study among healthy volunteers, saffron 400 mg daily for 7 days caused abnormal uterine bleeding in 2 women. 27 A study in the 1960s demonstrated uterine stimulant and estrogenic effects in guinea pigs and mice. 27 A high concentration of crocetin was teratogenic in frogs, 50 and an aqueous extract of saffron delayed bone ossification in mouse fetuses. 51

Amounts of more than 5 g are higher than the amounts used in food and may have uterine stimulant and abortifacient effects. 52 , 53 Avoid use.

Information regarding use in lactation is unavailable. Avoid use.


None well documented. 52 Conflicting results of saffron's effect on platelets were observed among healthy volunteers, while an aqueous extract of saffron inhibited human platelet aggregation in vitro. 27 , 32 Interactions with antiaggregating drugs is, thus, theoretically possible.

Crocetin binds strongly to serum albumin; however, displacement of plasma-bound drugs has not been evaluated. 11 , 30

Adverse Reactions

Clinical trials evaluating dosages of saffron 30 mg daily in depression reported no statistically significant adverse events versus either placebo or comparator drugs. Reported adverse effects include nausea, vomiting, and headache. 3 , 4

In a study among healthy volunteers, saffron 400 mg daily for 7 days caused statistically significant, but not clinically important, increases in serum creatine, sodium, and serum urea nitrogen. 27

Allergic reactions are uncommon; however, occupational allergy, including rhino-conjunctivitis, bronchial asthma, and cutaneous pruritus, has been reported. 54 , 55 Case reports of anaphylaxis exist. 4 , 56 Cross-sensitivity has been described among saffron and Lolium , Salsola , and Olea species. 55


Fatalities occurring from the use of saffron as an abortifacient have been cited. 27

The following effects were reported after ingestion of saffron 5 g: severe purpura, thrombocytopenia, and severe bleeding. 6 A lethal dose is considered to be 20 g and an abortifacient at 10 g. Nevertheless, saffron is generally not associated with toxicity when ingested in culinary amounts. 4

The median lethal dose has been estimated at 20.7 g/kg as a decoction in animal studies, 29 and saffron extract 600 mg/kg body weight for mice. 4

A few studies have evaluated the mutagenicity of saffron using the Ames/Salmonella test; concentrations of up to 1,500 mcg/plate have been found nontoxic and nonmutagenic. 3 , 25


1. USDA, NRCS. 2009. The PLANTS Database ( , June 2009). National Plant Data Center, Baton Rouge, LA 70874-4490 USA.
2. Bricklin M. The Practical Encyclopedia of Natural Healing . Emmaus, PA: Rodale Press Inc; 1976.
3. Abdullaev FI, Espinosa-Aguirre JJ. Biomedical properties of saffron and its potential use in cancer therapy and chemoprevention trials. Cancer Detect Prev . 2004;28(6):426-432.
4. Schmidt M, Betti G, Hensel A. Saffron in phytotherapy: pharmacology and clinical uses. Wien Med Wochenschr . 2007;157(13-14):315-319.
5. Evans WC. Trease and Evans' Pharmacognosy . 13th ed. London: Balliere Tindall; 1989.
6. Blumenthal M, ed. The Complete German Commission E Monographs . Boston, MA: American Botanical Council; 1998:371.
7. Hamilton GR, Baskett TF. In the arms of Morpheus: the development of morphine for postoperative pain relief. Can J Anesth . 2000;47(4):367-374. . Accessed December 8, 2009.
8. Ballabh B, Chaurasia OP, Ahmed Z, Singh SB. Traditional medicinal plants of cold desert Ladakh—used against kidney and urinary disorders. J Ethnopharmacol . 2008;118(2):331-339.
9. Bouvier F, Suire C, Mutterer J, Camara B. Oxidative remodeling of chromoplast carotenoids: identification of the carotenoid dioxygenase CsCCD and CsZCD genes involved in Crocus secondary metabolite biogenesis. Plant Cell . 2003;15(1):47-62. . Accessed March 2, 2004.
10. Tarantilis PA, Morjani H, Polissiou M, Manfait M. Inhibition of growth and induction of differentiation of promyelocytic leukemia (HL-60) by carotenoids from Crocus sativus L. Anticancer Res . 1994;14(5a):1913-1918.
11. Kanakis CD, Tarantilis PA, Tajmir-Riahi HA, Polissiou MG. Crocetin, dimethylcrocetin, and safranal bind human serum albumin: stability and antioxidative properties. J Agric Food Chem . 2007;55(3):970-977.
12. Carmona M, Zalacain A, Salinas MR, Alonso GL. A new approach to saffron aroma. Crit Rev Food Sci Nutr . 2007;47(2):145-159.
13. Duke JA. Handbook of phytochemical constituents of GRAS herbs and other economic plants . Boca Raton, FL: CRC Press; 1992.
14. Abe K, Sugiura M, Yamaguchi S, Shoyama Y, Saito H. Saffron extract prevents acetaldehyde-induced inhibition of long-term potentiation in the rat dentate gyrus in vivo. Brain Res . 1999;851(1-2):287-289.
15. Abdullaev FI. Inhibitory effect of crocetin on intracellular nucleic acid and protein synthesis in malignant cells. Toxicol Lett . 1994;70(2):243-251.
16. Escribano J, Alonso GL, Coca-Prados M, Fernandez JA. Crocin, safranal and picrocrocin from saffron ( Crocus sativus L.) inhibit the growth of human cancer cells in vitro. Cancer Lett . 1996;100(1-2):23-30.
17. Abdullaev FI, Frenkel GD. Effect of saffron on cell colony formation and cellular nucleic acid and protein synthesis. Biofactors . 1992;3(3):201-204.
18. Escribano J, Díaz-Guerra MJ, Riese HH, et al. In vitro activation of macrophages by a novel proteoglycan isolated from corms of Crocus sativus L. Cancer Lett . 1999;144(1):107-114.
19. Dhar A, Mehta S, Dhar G, et al. Crocetin inhibits pancreatic cancer cell proliferation and tumor progression in a xenograft mouse model [published correction appears in Mol Cancer Ther . 2009;8(3):711]. Mol Cancer Ther . 2009;8(2):315-323.
20. Tavakkol-Afshari J, Brook A, Mousavi SH. Study of cytotoxic and apoptogenic properties of saffron extract in human cancer cell lines. Food Chem Toxicol . 2008;46(11):3443-3447.
21. Nair SC, Kurumboor SK, Hasegawa JH. Saffron chemoprevention in biology and medicine: a review. Cancer Biother . 1995;10(4):257-264.
22. Nair SC, Pannikar B, Panikkar KR. Antitumour activity of saffron ( Crocus sativus ). Cancer Lett . 1991;57(2):109-114.
23. Salomi MJ, Nair SC, Panikkar KR. Inhibitory effects of Nigella sativa and saffron ( Crocus sativus ) on chemical carcinogenesis in mice. Nutr Cancer . 1991;16(1):67-72.
24. Garcia-Olmo DC, Riese HH, Escribano J, et al. Effects of long-term treatment of colon adenocarcinoma with crocin, a carotenoid from saffron ( Crocus sativus L.): an experimental study in the rat. Nutr Cancer . 1999;35(2):120-126.
25. Abdullaev FI. Cancer chemopreventive and tumoricidal properties of saffron ( Crocus sativus L.). Exp Biol Med (Maywood) . 2002;227(1):20-25. . Accessed September 10, 2003.
26. Grisolia S. Letter: Hypoxia, saffron, and cardiovascular disease. Lancet . 1974;2(7871):41-42.
27. Modaghegh MH, Shahabian M, Esmaeili HA, Rajbai O, Hosseinzadeh H. Safety evaluation of saffron ( Crocus sativus ) tablets in healthy volunteers. Phytomedicine . 2008;15(12):1032-1037.
28. Gainer JL, Jones JR. The use of crocetin in experimental atherosclerosis. Experientia . 1975;31(5):548-549.
29. Gainer JL, Chisolm GM III. Oxygen diffusion and atherosclerosis. Atherosclerosis . 1974;19(1):135-138.
30. Miller TL, Willett SL, Moss ME, Miller J, Belinka BA Jr. Binding of crocetin to plasma albumin. J Pharm Sci . 1982;71(2):173-177.
31. Chatterjee S, Poduval TB, Tilak JC, Devasagayam TP. A modified, economic, sensitive method for measuring total antioxidant capacities of human plasma and natural compounds using Indian saffron ( Crocus sativus ). Clin Chim Acta . 2005;352(1-2):155-163.
32. Jessie SW, Krishnakantha TP. Inhibition of human platelet aggregation and membrane lipid peroxidation by food spice, saffron. Mol Cell Biochem . 2005;278(1-2):59-63.
33. Akhondzadeh Basti A, Moshiri E, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Prog Neuropsychopharmacol Biol Psychiatry . 2007;31(2):439-442.
34. Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi AH, Khalighi-Cigaroudi F. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816]. BMC Complement Altern Med . 2004;4:12.
35. Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, et al. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytother Res . 2005;19(2):148-151.
36. Moshiri E, Basti AA, Noorbala AA, Jamshidi AH, Hesameddin Abbasi S, Akhondzadeh S. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial. Phytomedicine . 2006;13(9-10):607-611.
37. Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi AH. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. J Ethnopharmacol . 2005;97(2):281-284.
38. Sarris J. Herbal medicines in the treatment of psychiatric disorders: a systematic review. Phytother Res . 2007;21(8):703-716.
39. Thachil AF, Mohan R, Bhugra D. The evidence base of complementary and alternative therapies in depression. J Affect Disord . 2007;97(1-3):23-35.
40. Agha-Hosseini M, Kashani L, Aleyaseen A, et al. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. BJOG . 2008;115(4):515-519.
41. Xuan B, Zhou YH, Li N, Min ZD, Chiou GC. Effects of crocin analogs on ocular blood flow and retinal function. J Ocul Pharmacol Ther . 1999;15(2):143-152.
42. Laabich A, Vissvesvaran GP, Lieu KL, et al. Protective effect of crocin against blue light- and white light-mediated photoreceptor cell death in bovine and primate retinal primary cell culture. Invest Ophthalmol Vis Sci . 2006;47(7):3156-3163.
43. Maccarone R, Di Marco S, Bisti S. Saffron supplement maintains morphology and function after exposure to damaging light in mammalian retina. Invest Ophthalmol Vis Sci . 2008;49(3):1254-1261.
44. Abe K, Saito H. Effects of saffron extract and its constituent crocin on learning behaviour and long-term potentiation. Phytother Res . 2000;14(3):149-152.
45. Hosseinzadeh H, Younesi HM. Antinociceptive and anti-inflammatory effects of Crocus sativus L. stigma and petal extracts in mice. BMC Pharmacol . 2002;2:7. . Accessed September 10, 2003.
46. Brown AC, Hairfield M, Richards DG, McMillin DL, Mein EA, Nelson CD. Medical nutrition therapy as a potential complementary treatment for psoriasis—five case reports. Altern Med Rev . 2004;9(3):297-307.
47. Fornasier VL, Protzner K, Zhang I, Mason L. The prognostic significance of histomorphometry and immunohistochemistry in giant cell tumors of bone. Hum Pathol . 1996;27(8):754-760.
48. Debillon T, Gras-Leguen C, Vérielle V, et al. Intrauterine infection induces programmed cell death in rabbit periventricular white matter. Pediatr Res . 2000;47(6):736-742.
49. Lei M, Ghezzo H, Chen MF, Eidelman DH. Airway smooth muscle orientation in intraparenchymal airways. J Appl Physiol . 1997;82(1):70-77. . Accessed September 10, 2003.
50. Martin G, Goh E, Neff AW. Evaluation of the developmental toxicity of crocetin on Xenopus. Food Chem Toxicol . 2002;40(7):959-964.
51. Golalipour MJ, Gharravi AM, Ghafari S, Afshar M, Khori V. Effects of Crocus sativus on the fetal development of NMRI mice. Saudi Med J . 2008;29(2):309-310.
52. Brinker FJ. Herb Contraindications and Drug Interactions . 2nd ed. Sandy, OR: Eclectic Medical Publications; 1998.
53. Ernst E. Herbal medicinal products during pregnancy: are they safe? BJOG . 2002;109(3):227-235.
54. Martínez FV, Muñoz Pamplona MP, Urzaiz AG, García EC. Occupational airborne contact dermatitis from saffron bulbs. Contact Dermatitis . 2007;57(4):284-285.
55. Feo F, Martinez J, Martinez A, et al. Occupational allergy in saffron workers. Allergy . 1997;52(6):633-641.
56. Wüthrich B, Schmid-Grendelmeyer P, Lundberg M. Anaphylaxis to saffron. Allergy . 1997;52(4):476-477.

Copyright © 2009 Wolters Kluwer Health